In early 2022, Paul Chaplin, President and CEO of Copenhagen-based Bavarian Nordic A/S, was readying for a “rather heavy loss for the company.”
“It was going to be a challenging year, both because it was a huge year of investment in two Phase...
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
In early 2022, Paul Chaplin, President and CEO of Copenhagen-based Bavarian Nordic A/S, was readying for a “rather heavy loss for the company.”
“It was going to be a challenging year, both because it was a huge year of investment in two Phase...
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.